Skip to main content

Table 3 Clinical and immunological outcome

From: Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Blood-derived DC treated patient~Measurable disease sites at baselineaRadiological progression-free survival (mo)bOverall survival
(mo)
Dmc SKILseIFN-γc SKILseNumber of vaccinations
mDC-01Bone23.636.1c++9
mDC-0224.3c34.8c++9
mDC-0324.8c34.8c+9
mDC-04LN, bone3.428.0+3
mDC-05LN12.030.2c++6
mDC-06Bone3.423.3+3
mDC-07LN, bone3.417.1+3
pDC-01LN18.836.8c++9
pDC-02Bone6.424.9+6
pDC-03LN, bone3.420.03
pDC-04LN18.927.6c+9
pDC-05Bone6.127.6c+6
pDC-06LN23.9c37.8c+9
pDC-07LN, bone10.7d10.7+6
combiDC-01Bone4.241.2c3
combiDC-02Bone3.221.7+3
combiDC-033.720.4+3
combiDC-04Bone9.527.2c+6
combiDC-05Bone3.426.7c3
combiDC-06LN, bone9.725.6c+6
combiDC-07LN, bone12.024.4c++9
  1. DC dendritic cells, Dm dextramer, LN lymph nodes, mo months, SKILs skin-infiltrating lymphocytes
  2. ameasurable disease sites were determined on advanced imaging with contrast-enhanced 68Ga-prostate-specific membrane antigen (PSMA) PET/CT scans, for RECIST 1.1 and ferumoxtran-10-enhanced MRIs and MRI bones for PCWG2 criteria
  3. bradiological responses were assessed on contrast-enhanced 68Ga-PSMA PET/CT scans, ferumoxtran-10-enhanced MRIs and MRI lymph nodes for RECIST 1.1 and MRI bones for PCWG2 criteria. In case of progressive disease according to RECIST 1.1 and/or PCWG2 criteria a confirmatory MRI lymph nodes and bones was performed 6–8 weeks later. The date used for calculation of progression-free survival was the first date at which progression criteria were met (the date of unconfirmed progression of disease)
  4. cprogression-free survival or overall survival endpoint not reached in this patient
  5. dpatient had stable disease according to RECIST 1.1 and PCWG2 criteria. At 10.7 months after apheresis patient deceased due to a ruptured type A acute aortic dissection
  6. etetramer- or dextramer-positivity (dm+) or IFN-γ-positivity of SKILs if at least for one epitope CD8+ dm+ or IFN-γ+ T cells were detected